Every year scores of new pharmaceuticals enter the market, almost never with human fetal safety data. Such data typically accumulate during the "rst years of clinical use, in the form of case reports, case series, prospective and retrospective cohorts and case control studies. All of these methods su#er from serious sources of bias, o$en leading to alarming signals of teratogenicity that are la...